Abstracts Archive - Page 578 of 2425 - ACR Meeting Abstracts

Abstract Number: 0389 • ACR Convergence 2021
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States
Elana Bernstein¹, John VanBuren², Shervin Assassi³, Flavia Castelino⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech², Emily Startup², Jessica Gordon⁸, Faye Hant⁹, Laura Hummers¹⁰, Nora Sandorfi¹¹, Ami Shah¹², Victoria Shanmugam¹³, Virginia Steen¹⁴ and Dinesh Khanna¹⁵, ¹Columbia University, New York, NY, ²University of Utah, Salt Lake City, UT, ³University of Texas McGovern Medical School at Houston, Houston, TX, ⁴Massachusetts General Hospital, Boston, MA, ⁵Stanford University, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸Hospital for Special Surgery, New York, NY, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Johns Hopkins Univerisity, Baltimore, MD, ¹¹University of Pennsylvania, Philadelphia, PA, ¹²Johns Hopkins Rheumatology, Baltimore, MD, ¹³The George Washington University, Great Falls, VA, ¹⁴Division of Rheumatology, Georgetown University, Washington, DC, ¹⁵University of Michigan, Ann Arbor, MI
Background/Purpose: Interstitial lung disease (ILD) affects 40-60% of adults with systemic sclerosis (SSc) and is the leading cause of death in this population. Nintedanib, a…
Abstract Number: 0388 • ACR Convergence 2021
Prediction Tool for Damage Accrual Trajectory in Incident Systemic Sclerosis
Ariane Barbacki¹, Ada Man², Mianbo Wang³, Dylan Johnson⁴, Yuqing Zhang⁵, Mandana Nikpour⁶ and Murray Baron⁷, ¹McGill University, Montral, Montréal, QC, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³Lady Davis institute for Medical Research, Montréal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Massachusetts General Hospital, Quincy, MA, ⁶University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ⁷Jewish General Hospital, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) is a systemic autoimmune disease associated with the accrual of organ damage over time, which can be measured using the Scleroderma…
Abstract Number: 0387 • ACR Convergence 2021
Predictors for Progressive Fibrosis in Patients with Connective Tissue Disease Associated Interstitial Lung Diseases
Yu-Hsiang Chiu¹, Julia Spierings², Pim de Jong¹, Firdaus Mohamed Hoesein¹, Jan Grutters³, Jacob van Laar¹ and Mareye Voortman¹, ¹University Medical Centre Utrecht, Utrecht, Netherlands, ²University Medical Center Utrecht, Utrecht, Netherlands, ³St. Antonius Hospital, Nieuwegein, Netherlands
Background/Purpose: Connective tissue disease associated interstitial lung disease (CTD-ILD) is associated with decreased quality of life and high mortality risk. Outcome and treatment response is…
Abstract Number: 0382 • ACR Convergence 2021
Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Carolina Tornero¹, Victoria Navarro-Compán², raquel almodovar³, Cristina fernández-Carballido⁴, Azucena Hernández⁵, Beatriz Joven-Ibáñez⁶, Xavier Juanola⁷, M.Lourdes Ladehesa-Pineda⁸, José Ramón maneiro⁹, Antoni Juan Mas¹⁰, carlos Montilla¹¹, Manuel J Moreno¹², Mireia moreno¹³, José A. pinto¹⁴, juan Carlos Quevedo¹⁵, José Rosas¹⁶, Teresa Ruiz¹⁷, Jesús Sanz¹⁸ and Eugenio De Miguel¹⁹, ¹University Hospital La Paz, Madrid, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Hospital Universitario Fundación de Alcorcón, Madrid, Spain, ⁴H. San Juan, Alicante, Alicante, Spain, ⁵Hospital Virgen de la Salud, Toledo, Spain, ⁶University Hospital 12 de Octubre, Madrid, Spain, ⁷Hospital Universitari de Bellvitge, Barcelona, Spain, ⁸Hospital Universitario Reina Sofía, Córdoba, Spain, ⁹Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Galicia, Spain, ¹⁰Hospital Universitario Son Llàtzer, Palma de Mallorca, Spain, ¹¹Hospital Universitario de Salamanca, Salamanca, Spain, ¹²Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain, ¹³Parc Taulí Hospital Universitari. Institut d’Investigació i Innovació Parc Taulí I3PT, Sabadell, Spain, ¹⁴Complejo Hospitalario Universitario de A Coruña (CHUAC), A Coruña, Spain, ¹⁵Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ¹⁶Hospital Marina Baixa, Villajoyosa, ¹⁷Hospital de Sierrallana, Servicio de Reumatología, Torrelavega, Spain, ¹⁸Hospital Universitario Puerta de Hierro, Madrid, Spain, ¹⁹Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Esperanza was a multicenter national health program developed to facilitate an early diagnosis of patients with Spondyloarthritis (SpA) in Spain. The main objective of…
Abstract Number: 0393 • ACR Convergence 2021
Severity and Impact of Gastrointestinal Symptoms in Patients with SSc-ILD Treated with Nintedanib: Data from SENSCIS-ON
Dinesh Khanna¹, Elizabeth Volkmann², Kristin B Highland³, Yannick Allanore⁴, Stéphane Jouneau⁵, James R Seibold⁶, Alexandra James⁷, Margarida Alves⁸ and Oliver Distler⁹, ¹University of Michigan, Ann Arbor, MI, ²Department of Medicine, Division of Rheumatology, University of California, David Geffen School of Medicine, Los Angeles, CA, ³Cleveland Clinic, Cleveland, OH, ⁴Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, ⁵Department of Respiratory Medicine, Competences Centre for Rare Pulmonary Diseases, Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France, Rennes, France, ⁶Scleroderma Research Consultants LLC, Aiken, SC, ⁷Elderbrook solutions GmbH, Bietigheim-Bissingen, Germany, Bietigheim-Bissingen, Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ⁹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland
Background/Purpose: Gastrointestinal (GI) involvement is a common manifestation of systemic sclerosis (SSc) and a frequent side-effect of drugs used to treat SSc. In the SENSCIS…
Abstract Number: 0392 • ACR Convergence 2021
Faecal Incontinence in Scleroderma: Prevalence, Impact and Response to Sacral Neuromodulation in an Single Centre Observational Cohort
Nikhil Suresh¹, Ranjitha Karanth¹, David Jayne², Giuseppina Abignano³ and Francesco Del Galdo³, ¹LIRMM, Leeds, United Kingdom, ²Colorectal Surgery / St James University Hospital, Leeds, United Kingdom, ³University of Leeds, Leeds, United Kingdom
Background/Purpose: Scleroderma (SSc) is a chronic autoimmune disorder involving multiple organs, the gastrointestinal system (GI) commonly involved in up to 90% of the sufferers. Faecal…
Abstract Number: 0390 • ACR Convergence 2021
Vaccination Against COVID-19: Self-Reported Experiences of Patients with Systemic Sclerosis in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort
Kimberly Showalter¹, Jessica Gordon¹, Yin Wu², Linda Kwakkenbos³, Marie-Eve Carrier⁴, Richard Henry², Nora Østbø², Julia Nordlund², Angelica Bourgeault², Mara Canedo Ayala², Marie-Nicole Discepola², Andrea Carboni Jiménez², Christopher Denton⁵, Luc Mouthon⁶, Brett Thombs⁷ and Robert Spiera¹, ¹Hospital for Special Surgery, New York, NY, ²Lady Davis Institute of the Jewish General Hospital, Montréal, QC, Canada, ³Department of Clinical Psychology, Radboud University Behavioural Science Institute, Nijmegen, Netherlands, ⁴Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, QC, Canada, ⁵University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom, ⁶Centre de Référence Maladies Autoimmunes Systémiques Rares d'Ile de France, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ⁷Lady Davis Institute for Medical Research, Jewish General Hospital; Department of Psychiatry, McGill University, Montréal, QC, Canada
Background/Purpose: COVID-19 vaccination is recommended for individuals with rheumatic diseases, yet data are limited regarding vaccine safety in this population, particularly among those with rare…
Abstract Number: 0394 • ACR Convergence 2021
Hyperspectral Imaging in Systemic Sclerosis-Raynaud Phenomenon
Akash Gupta¹, Shannon Teaw², Alyssa Williams², F. Perry Wilson³, Brandon Sumpio⁴, Bauer Sumpio⁴ and Monique Hinchcliff⁵, ¹Department of Medicine, Yale University School of Medicine, New Haven, CT, ²Section of Rheumatology, Allergy & Immunology, Department of Medicine, Yale School of Medicine, New Haven, CT, ³Section of Nephrology, Department of Medicine, Yale School of Medicine, New Haven, CT; Department of Medicine Clinical and Translational Research Accelerator Yale School of Medicine, New Haven, CT, ⁴Division of Vascular Surgery, Department of Surgery, Yale School of Medicine, New Haven, CT, ⁵Yale School of Medicine, Westport, CT
Background/Purpose: Raynaud phenomenon (RP), a microcirculatory, vasospastic disorder, may be primary or secondary to an autoimmune disease [e.g., an early indicator of systemic sclerosis (SSc)].…
Abstract Number: 0396 • ACR Convergence 2021
Esophageal Involvement and Gastroesophageal Reflux Disease in Patients with SSc-ILD: Data from a Sub-Study of the SENSCIS Trial
Michael Kreuter¹, Dinesh Khanna², Christopher Ryerson³, Stephen Humphries⁴, Tohru Takeuchi⁵, Mark Hamblin⁶, Dag Wormanns⁷, Carina Ittrich⁸, Frank Risse⁸, Margarida Alves⁹ and David Lynch⁴, ¹Center for Interstitial and Rare Lung Diseases, Pneumology and Respiratory Care Medicine, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany, ²University of Michigan, Ann Arbor, MI, ³Department of Medicine & Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada, Vancouver, BC, Canada, ⁴Department of Radiology, National Jewish Health, Denver, CO, ⁵Osaka Medical and Pharmaceutical University, Osaka, Japan, ⁶University of Kansas Hospital, Kansas City, KS, ⁷Evangelische Lungenklinik, Berlin, Germany, ⁸Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany
Background/Purpose: Upper gastrointestinal involvement such as esophageal dilation is frequently observed in patients with SSc-ILD and may be associated with the presence or severity of…
Abstract Number: 0395 • ACR Convergence 2021
RNA Polymerase III Autoantibody Levels and Risk of Systemic Sclerosis in Patients with Raynaud Phenomenon
Megan Lockwood¹, Yuqing Zhang², Marcy Bolster¹, Sara Schoenfeld¹, Xiaoqing Fu¹, Seth Brownmiller¹, Ana Fernandes¹ and Flavia Castelino¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Quincy, MA
Background/Purpose: Raynaud phenomenon is often the initial manifestation in systemic sclerosis (SSc) and can precede other SSc symptoms by years (1). Several SSc-specific autoantibodies are…
Abstract Number: 0391 • ACR Convergence 2021
High Frequency Ultrasound Imaging of Skin Thickness in Patients with Early Diffuse Cutaneous Systemic Sclerosis: An Objective Outcome Measure to Track Change over Time
Elizabeth Marjanovic¹, Calvin Heal¹, Tonia Moore¹, Joanne Manning², Sarah Wilkinson¹, Graham Dinsdale², Mark Dickinson¹, Jack Wilkinson¹, Ariane Herrick³ and Andrea Murray¹, ¹University of Manchester, Manchester, United Kingdom, ²Salford Royal NHS Foundation Trust, Manchester, United Kingdom, ³University of Manchester, Salford, United Kingdom
Background/Purpose: There are currently no validated objective measures of systemic sclerosis (SSc)-related skin thickening and this hampers clinical trials of potential new treatments. The modified…
Abstract Number: 0385 • ACR Convergence 2021
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Michal Sagiv¹, Abid Awisat², Aniela Shouval², Regina Peri³, Mohammad Adawi⁴, Firas Sabbah⁴, Itzhak Rosner², Aharon Kessel³ and Gleb Slobodin², ¹Faculty of Medicine, Bar Ilan University, Tel Aviv, Israel, ²Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ³Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel, ⁴Puria Medical Center, Tiberias, Israel
Background/Purpose: There is an unmet need for a reliable biomarker for the diagnosis and differentiation of AxSpA from its multiple mimickers. Serum levels of IL-22,…
Abstract Number: 0366 • ACR Convergence 2021
Why Is It so Difficult for AxSpA Patients to Find a Job? Results from the European Map of Axial Spondyloarthritis (EMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro-Compán², Christine Bundy³, Souzi Makri⁴, Laura Christen⁵, José Correa-Fernández⁶, Sergio Sanz-Gomez⁶, Raj Mahapatra⁷, Carlos Jesús Delgado-Domínguez⁶ and Denis Poddubnyy⁸, ¹Health & Territory Research (HTR), University of Seville, Sevilla, Spain, ²Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ³Cardiff University, Cardiff, Wales, United Kingdom, ⁴Cyprus League Against Rheumatism (CYPLAR), Limassol, Cyprus, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, ⁷Axial Spondyloarthritis International Federation (ASIF), London, United Kingdom, ⁸Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: AxSpA is associated with substantial negative consequences regarding work status and career prospects. The aim is to identify factors associated with barriers to job…
Abstract Number: 0337 • ACR Convergence 2021
Rarity of Pneumocystis Jirovecii Pneumonia in Patients with Systemic Lupus Erythematosus Using a Real-world, Electronic Health Record
Ben Boone and April Barnado, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Infection is the leading cause of mortality and one of the most common causes of hospitalization in patients with systemic lupus erythematosus (SLE). Pneumocystis…
Abstract Number: 0274 • ACR Convergence 2021
Angiopoietin-Like Protein 4, Apolipoprotein C3 and Lipoprotein Lipase Axis in the Abnormal Lipid Profile of Patients with Rheumatoid Arthritis: Relation to Subclinical Atheromatosis
juan Carlos Quevedo¹, Laura de Armás-Rillo², Antonia de Vera-González³, Laura Cáceres¹, Cristina Almeida¹, Alejandra González-Delgado³ and Iván Ferraz-Amaro³, ¹Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain, ²Universidad Europea de Canarias, Santa Cruz De Tenerife, Spain, ³Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with an increase in cardiovascular (CV) risk, attributed, among other factors, to the existence of an abnormal lipid profile.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].